NCT06799143

Brief Summary

To evaluate longer-term (5-7 years) outcomes of the twelve (12) subjects treated with AGN1 Femoral LOEP in the clinical study "A Prospective Pilot Evaluation of Percutaneous Osteo-supplementation in the Proximal Femur of Osteoporotic Patients". Performance will be evaluated via medical history evaluation, X-ray, DXA, CT and mobility testing. The study will look at the extent to which the benefits demonstrated in the initial, baseline study were sustained over time. In this manner, it may be possible to determine the rate of change in BMD following the treatment; thereby allowing prediction of the total benefit period. In addition, this longer period of observation allows for further evaluation of the safety profile of the material in osteoporosis patients.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2016

Shorter than P25 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 13, 2016

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 25, 2016

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 15, 2016

Completed
8.8 years until next milestone

First Submitted

Initial submission to the registry

January 17, 2025

Completed
12 days until next milestone

First Posted

Study publicly available on registry

January 29, 2025

Completed
Last Updated

January 29, 2025

Status Verified

January 1, 2025

Enrollment Period

1 month

First QC Date

January 17, 2025

Last Update Submit

January 23, 2025

Conditions

Keywords

LOEPosteoporosisfemur fracture

Outcome Measures

Primary Outcomes (9)

  • Bone Mineral Density

    Bone mineral density (BMD) assessed by DXA scans (T-score ) of the treated hip compared to nontreated hip (femoral neck).

    through study completion, an average of 30 days

  • Bone Mineral Density

    Bone mineral density (BMD) assessed by DXA scans (absolute value measurement) of the treated hip compared to nontreated hip (femoral neck).

    through study completion, an average of 30 days

  • Bone Mineral Density

    Percent change compared to baseline for the treated femoral neck measurement of BMD.

    through study completion, an average of 30 days

  • Bone Mineral Density

    Percent change compared to baseline for the untreated femoral neck measurement of BMD.

    through study completion, an average of 30 days

  • Bone Mineral Density

    Bilateral hip CT scan analysis of the trabecular bone density.

    through study completion, an average of 30 days

  • Bone Mineral Density

    Bilateral hip CT scan analysis of the trabecular bone volume.

    through study completion, an average of 30 days

  • Bone Mineral Density

    Bilateral hip CT scan analysis of the cortical bone density.

    through study completion, an average of 30 days

  • Bone Mineral Density

    Bilateral hip CT scan analysis of the cortical bone volume.

    through study completion, an average of 30 days

  • Bone Mineral Density

    Bilateral hip CT scan analysis of any qualitative observations compared to baseline CT scans.

    through study completion, an average of 30 days

Secondary Outcomes (4)

  • Subject Interview

    through study completion, an average of 30 days

  • Subject Interview

    through study completion, an average of 30 days

  • Subject Interview

    through study completion, an average of 30 days

  • FRAX Index Risk Assessment

    through study completion, an average of 30 days

Eligibility Criteria

Age56 Years+
Sexfemale(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Females aged 56 or older and menses have ceased for at least one year. Subjects that were participants in the original study that signed a consent form, received treatment with AGN1 Femoral LOEP and completed the original study.

You may qualify if:

  • participated in the original study and signed the consent form
  • received treatment with AGN1 Femoral LOEP
  • completed the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Proximal Femoral FracturesOsteoporosisFemoral Fractures

Condition Hierarchy (Ancestors)

Femoral Neck FracturesHip FracturesFractures, BoneWounds and InjuriesHip InjuriesLeg InjuriesBone Diseases, MetabolicBone DiseasesMusculoskeletal DiseasesMetabolic DiseasesNutritional and Metabolic Diseases

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
OTHER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 17, 2025

First Posted

January 29, 2025

Study Start

January 13, 2016

Primary Completion

February 25, 2016

Study Completion

April 15, 2016

Last Updated

January 29, 2025

Record last verified: 2025-01